Current Partnering seeks out the biopharma partnering best articles from various sources, to keep you updated on partnering best practice and broader topics currently being discussed and debated.
Want to be alerted to latest biopharma partnering articles? Signup for our Dealmaker’s Update email newsletter.
Want to submit content? Contact us to discuss further.
Regeneron Pharmaceuticals is Biopharmaceutical Company focusing on the development of human antibody technologies for the treatment of a number of different diseases.
Regeneron Pharmaceuticals announced around 18 partnering / licensing deals since 2009. more »
February 25, 2014 : best practice, evaluation, industry trends, option
The article here analyses the recent partnering industry trends in the option and evaluation deal type areas. There are two major forms of deal terms that allow a party to secure rights to an asset subject to a future event more »
February 24, 2014 : biotech, cystic fibrosis, hep c, Vertex
Vertex Pharmaceuticals is a global biotechnology company creating new possibilities in medicines, specifically for the diseases hepatitis C and Cystic Fibrosis. more »
Vertex has announced only 1 M&A deal since 2009, with the acquisition of ViroChem. more »
Vertex Pharmaceuticals, a biotechnology company founded in 1989 and headquartered in Massachusetts has rapidly risen as one of the leading biotechnology companies in the world. more »
February 18, 2014 : deal analysis, orphan, partnering
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
Ipsen merger and acquisition deals during 2009-2014 in pharmaceuticals reviewed. more »
Ipsen is a specialty pharmaceutical company listed as one of the top 50 bigbiotech companies by Current Partnering (listed by 2012 revenue). more »
Ipsen is a French specialty pharmaceutical company developing products to increase life expectancy. more »
With over 450 deals announced, 2013 was a big year for mergers and acquisitions in the life sciences more »
February 11, 2014 : biomarkers, industry trends, partnering
Recent advances in biomarkers, pharmacogenomics, bioinformatics and companion diagnostics have raised opportunities in the emerging field of personalized medicine more »
February 11, 2014 : big biotech, big pharma, deal analysis, points of view
This month we provide you with an overview of deal analysis life science deal making activity, covering partnering, M&A and financing in January 2014. more »
February 10, 2014 : Actelion, biotechnology, cardiovascular
Actelion is a Switzerland based biopharmaceutical company discovering, developing and commercializing products for unmet medical needs. more »
Actelion has announced only 1 M&A deal since 2009, with the deal being the acquisition of Ceptaris Therapeutics. more »
Actelion, a big biotech company based in Switzerland, has a fully integrated business model focused on innovative treatments to serve high unmet medical needs. more »
February 4, 2014 : best practice, partnering, partnering agreements, partnering terms, preclinical
Recent trends in preclinical partnering for the top pharma and biotech companies reviewed, over 2,000 deals analyzed – including summary of biopharma deal financials more »
Ranbaxy is a research based pharmaceutical company with a strong focus on developing generics. more »